Encellin

Encellin is a private, clinical-stage biotech based in San Francisco, pioneering a novel cell encapsulation platform. The company's lead application is for hypoglycemia in Type 1 Diabetes, with an interim clinical readout showing promising early results, including non-fibrotic engraftment. Founded on technology from UCSF, Encellin aims to enable durable, off-the-shelf cell replacement therapies across a range of chronic conditions, beginning with high-unmet-need endocrine disorders.

Encapsulated Cell Replacement Therapy (ENCRT): A nano-porous, biocompatible polymer pouch implant designed to protect therapeutic cells from immune rejection without systemic immunosuppression, allowing for exchange of nutrients and therapeutic molecules.

Encellin competes in the cell encapsulation and immune-protection space, which includes companies like Sernova (Cell Pouch), ViaCyte (now part of Vertex), and Beta-O2. It also faces indirect competition from advanced insulin pumps/closed-loop systems and other cell therapy approaches for diabetes. Its differentiation lies in its nano-porous membrane technology and early clinical data showing a lack of fibrotic response.